113 completed, 40 terminated, 33 active not recruiting, 33 recruiting. 258 Phase 2, 58 Phase 1, 8 Phase 3.
Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 43 | 2026-09-16 | 2026-11-17 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Chidamide, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Ou Bai, MD/PHD | 50 | 2026-04-30 | 2026-03-25 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-10-30 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab), Placebo - Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I | Phase 2 | Recruiting | PolTREG S.A. | 150 | 2025-03-12 | 2026-07-17 |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 27 | 2025-01-22 | 2026-03-13 |
| Epco, Zanu, Ritux for R/R FL or MZL Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Reid Merryman, MD | 71 | 2025-01-21 | 2026-09-25 |
Showing 20 of 258. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (69) · Lymphoma, Mantle-Cell (56) · Lymphoma, Follicular (52) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Lymphoma, Non-Hodgkin (40) · Burkitt Lymphoma (38) · Lymphoma, B-Cell, Marginal Zone (36) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Waldenstrom Macroglobulinemia (26) · Lymphoma (23) · Lymphoma, B-Cell (17) · Hodgkin Disease (15) · Lymphoma, Large-Cell, Immunoblastic (14) · Recurrence (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9)
M.D. Anderson Cancer Center (44) · National Cancer Institute (NCI) (31) · University of Washington (12) · City of Hope Medical Center (11) · Fred Hutchinson Cancer Center (10) · Mayo Clinic (6) · Hoffmann-La Roche (4) · Northwestern University (4) · Academic and Community Cancer Research United (3) · Arbeitsgemeinschaft medikamentoese Tumortherapie (3) · Fudan University (3) · Stanford University (3) · The Lymphoma Academic Research Organisation (3) · Asan Medical Center (2) · Case Comprehensive Cancer Center (2)
United States (182) · Italy (18) · United Kingdom (18) · France (12) · Germany (11) · China (10) · South Korea (9) · Australia (8) · Belgium (7) · Canada (7) · Spain (6) · Austria (5) · Mexico (5) · Poland (4) · Brazil (3)
Elias Jabbour (7) · Ajay Gopal (4) · Thomas Witzig (3) · Ye Guo, MD (3) · David Gomez-Almaguer, MD (2) · David Maloney (2) · Deepa Jagadeesh, MD, MPH (2) · Edmund Kwok Ming LI, MD (2) · Farhad Ravandi-Kashani (2) · Geoffrey Shouse (2) · Grzegorz S Nowakowski (2) · Issa F Khouri (2) · Issa Khouri (2)
PMID 39319495, PMID 34515338, PMID 34797699, PMID 35952327, PMID 39513526, PMID 41671463, PMID 12907446, PMID 17687130, PMID 20023215, PMID 20039397, PMID 20039413, PMID 20131246, PMID 20841509, PMID 21325353, PMID 21440503, PMID 21478218, PMID 21508413, PMID 21821712, PMID 22535574, PMID 22734071, PMID 23401442, PMID 23547837, PMID 23592273, PMID 23753028, PMID 23753030, PMID 23799873, PMID 23834234, PMID 24297953, PMID 24458437, PMID 24516013, PMID 24638012, PMID 25304612, PMID 25343233, PMID 25439689, PMID 26065651, PMID 26248505, PMID 26250576, PMID 26378033, PMID 26432046, PMID 26640039, PMID 26643449, PMID 26844479, PMID 27018242, PMID 27118452, PMID 27132696, PMID 27530379, PMID 27536708, PMID 28314744, PMID 28314788, PMID 28637670
P30CA015704 (10), P30CA033572 (9), P30CA016672 (7), P30CA015083 (5), U10CA180821 (5), 2009 (4), U10CA021115 (4), U10CA031946 (4), P30CA060553 (3), U10CA025224 (3), U10CA032102 (3), U10CA180820 (3), U10CA180888 (3), 2015 (2), 2016 (2)